Guggenheim has initiated coverage of Metsera (MTSR) with a buy rating, citing the company's obesity drug candidates. Read ...
Eli Lilly said it has launched new doses of its obesity treatment drug and reduced its prices.
Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s differentiated obesity drug pipeline and potential for significant upside. Metsera is also viewed as a ...
Metsera Inc. (MTSR), a New York-based biotech that went public on Jan. 31 with some fanfare, has a full portfolio of weight-loss drugs in development, using both the hormones already used in existing ...
Guggenheim has initiated Metsera at buy saying that the biotech's pipeline of injectable and oral nutrient stimulated hormone ...
Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...
Metformin is an old drug. In its earliest form, it was an extract from lilacs and was purportedly used in the 1700s to treat ...
BofA initiated coverage of Metsera (MTSR) with a Buy rating and $38 price target implying over 20% share upside. Metsera is a clinical-stage ...
Guggenheim initiated coverage of Metsera (MTSR) with a Buy rating and $56 price target The firm sees a “highly promising multi-billion ...
Aardvark Therapeutics has followed up filings and speculation with a $94 million initial public offering, putting itself on ...
NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR) ("Metsera”), a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone ...
Are you on a weight loss journey but struggling to shed those extra kilos? You're not alone. Many people often feel lost about what to eat and do to reach their fitness goals, sometimes blindly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results